Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Crispr Therapeutics Ord Shs (NQ: CRSP)
89.60 USD  -3.72 (-3.99%)
Streaming Delayed Price  /  Updated: 11:45 AM EDT, Jul 16, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 295,183
Open 91.60
Bid (Size) 89.59 (1)
Ask (Size) 89.67 (1)
Prev. Close 93.32
Today's Range 89.43 - 92.60
52wk Range 32.30 - 97.82
Shares Outstanding 46,842,969
Dividend Yield N/A
Performance
YTD
+51.05%
+51.05%
1 Month
+43.47%
+43.47%
3 Month
+86.16%
+86.16%
6 Month
+50.44%
+50.44%
1 Year
+84.74%
+84.74%
Top News
More News
BioMedNewsBreaks – CRISPR Therapeutics (NASDAQ: CRSP) Secures $517.5M in Underwritten Public Offering
from InvestorBrandNetwork
It's One Of This Year's Best Health Care ETFs And It Doesn't Own Any Moderna
When it comes to health care exchange-traded funds in 2020, it's a case of haves and have nots. What To Know:The health ... Read More
category Top Stories , Biotech , Sector ETFs , and 11 more.
from Benzinga
More News
Read More
CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares
from GlobeNewswire News Releases
Technical Analysis: BABA, CRSP, NSTG, XONE, MTLS and PRLB
category Stocks / Equities
from Blogs - TalkMarkets
Is Intellia Therapeutics Stock a Buy?
category CRSP , BLUE , NVS , and 3 more.
from Motley Fool
3 Absolutely Rock-Solid Stocks to Buy Before the Market Crashes Again
category DG , CRSP , WMT , and 4 more.
from Motley Fool
Could This Biotech Stock Leader Become A Winner In New Treatments?
from Investor's Business Daily
Alibaba, Crispr Therapeutics, NanoString - Technical Analysis
category Stocks / Equities
from Blogs - TalkMarkets
Here's Why CRISPR Therapeutics Shares Jumped 13.8% in June
category VRTX , CRSP , Market News
from Motley Fool
August 14th Options Now Available For CRISPR Therapeutics (CRSP)
category Stocks
from Market News Video
Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis
from Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.